Changing of the Guard in Health Care Fraud: An Interview With Michael Loucks
This article was originally published in RPM Report
Executive Summary
Michael Loucks stepped down as acting US Attorney at the end of 2009, after a career that put him at the center of many of the largest health care fraud prosecutions in the pharmaceutical industry. We spoke to him about what happens next, for industry, for prosecutors-and for him.
You may also be interested in...
Where is the Waste in Part D?
Rooting out waste in federal health care spending is one of few points of perennial bipartisan agreement in health policy. In that spirit, a Senate Committee wants to focus on trimming the waste in the Medicare pPrescription drug program-but first they have to figure out where it is.
The Era of Big Pharma Fraud Cases Is Ending, Former US Attorney Loucks Says, But It May Go Out With A Bang
The pace of whistleblower cases against Big Pharma companies is winding down, former prosecutor says. It may not seem that way, with a full pipeline of pending investigations likely to dominate the headlines for months or even years to come, but Big Pharma is finally coming into compliance. This era may end with a bang: Loucks believes there is significant pressure to exclude a corporation for fraud.
The Era of Big Pharma Fraud Cases Is Ending, Former US Attorney Loucks Says, But It May Go Out With A Bang
The pace of whistleblower cases against Big Pharma companies is winding down, former prosecutor says. It may not seem that way, with a full pipeline of pending investigations likely to dominate the headlines for months or even years to come, but Big Pharma is finally coming into compliance. This era may end with a bang: Loucks believes there is significant pressure to exclude a corporation for fraud.